J.B. Chemicals & Pharmaceuticals Limited reported a 6% increase in consolidated revenue to ₹4,148 crore for the financial year ended March 31, 2026. The company’s operating EBITDA grew by 8% to ₹1,178 crore, and profit after tax rose by 8% to ₹709 crore.

The growth was driven by a favourable product mix and stable costs, which supported gross margin expansion. On a consolidated basis, revenue stood at ₹4,14,779 lakhs, registering a 6% year-on-year growth. EBITDA margins improved to 28.4% adjusted for non-recurring items.

The domestic formulations business grew 9% to ₹24,735.4 lakhs, outperforming the Indian Pharmaceutical Market. The international business recorded revenue growth of 2% to ₹16,742.5 lakhs, supported by a healthy order pipeline in the CDMO segment.

Financial Highlights

The board has recommended a final dividend of ₹9.30 per equity share for FY26. The interim dividend of ₹12.70 per share was paid on February 25, 2026.

J.B. Chemicals & Pharmaceuticals Limited has announced that its 50th Annual General Meeting (AGM) will be held on June 17, 2026, at 3:00 p.m. IST via Video Conferencing (VC). The meeting will be conducted to transact business, including the adoption of financial statements for the year ended March 31, 2026, and the declaration of dividends. The record date for determining shareholder eligibility for dividend entitlement is fixed as May 29, 2026.

The board has proposed a final dividend of ₹ 9.30 per equity share for the financial year 2025-26. Additionally, the meeting will seek confirmation for an interim dividend of ₹ 12.70 per equity share already paid during the financial year. If declared, the final dividend is scheduled to be paid on or after June 19, 2026, subject to tax deduction at source.

Agenda and Appointments

The AGM will consider the adoption of the audited financial statements and consolidated financial statements for the year ended March 31, 2026. Shareholders will also vote on the re-appointment of Mr. Amal Kelshikar (DIN: 06378987), who retires by rotation and is eligible for re-appointment. Mr. Kelshikar currently oversees the India business of Torrent Pharmaceuticals Limited and brings over 32 years of experience in strategic planning and marketing.

E-Voting and Participation Details

Remote e-voting facilities will be available from June 14, 2026, at 9:00 a.m. to June 16, 2026, at 5:00 p.m. Shareholders holding shares as on the cut-off date of June 10, 2026, are eligible to cast their votes. The company has engaged Central Depository Services (India) Limited (CDSL) to facilitate the electronic voting process.

Shareholders holding physical shares are requested to ensure their KYC details, including PAN and bank account information, are updated to receive dividends electronically. The company has advised members to utilize the Electronic Clearing System (ECS) for seamless dividend receipt.